Business Context and Reporting Period
Priveterra Acquisition Corp. filed this Form 8-K on June 13, 2023 under Item 8.01 in connection with its proposed business combination with AEON Biopharma, Inc. The filing updates the company’s definitive proxy materials for the special stockholder meeting.
Key Financial Metrics
This filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other financial metrics. It is focused on the special meeting and proxy disclosures.
Material Changes Versus Prior Disclosure
- The special meeting originally scheduled for June 13, 2023, at 12:00 p.m. Eastern Time was adjourned to June 15, 2023, at 12:00 p.m. Eastern Time.
- The rescheduled meeting will be held virtually at www.virtualshareholdermeeting.com/PMGM2023SM.
- Priveterra supplemented its definitive proxy statement to disclose the adjournment. The filing states that the meeting location, record date, redemption deadline, and other proposals were unchanged.
- Stockholders who already submitted proxies and do not wish to change their votes need not take further action. Stockholders of record as of April 11, 2023, remain eligible to vote even if they later sold their shares.
- Stockholders seeking to withdraw a redemption request could do so before the rescheduled meeting by requesting that the transfer agent return their shares.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no operating guidance or financial outlook. It includes customary forward-looking statement disclaimers relating to the proposed transaction and future performance of Priveterra and AEON. Risks and uncertainties are referenced in the company’s IPO prospectus, definitive proxy statement, related S-4 registration statement, and other SEC filings.
The principal unusual item is the adjournment of the special meeting to allow additional time for Priveterra to engage with stockholders.
Important Facts for Investors to Verify
- Whether stockholders approved the business combination proposal at the rescheduled June 15, 2023 meeting.
- The final number of shares redeemed and the resulting cash available to the combined company.
- Whether all closing conditions for the Priveterra-AEON transaction were satisfied and when the transaction closed.
- The definitive proxy statement and related S-4 registration statement for transaction terms, pro forma financial information, capitalization, and risk factors.
- Any subsequent SEC filings reporting the meeting outcome, transaction closing, or changes to the redemption process.